William Sandborn
University of California, San Diego
H-index: 198
North America-United States
Top articles of William Sandborn
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
P957 Subcutaneous infliximab (CT-P13 SC) for ulcerative colitis: 2-year extension results of the LIBERTY-UC study | Journal of Crohn's and Colitis | BE Sands SB Hanauer JF Colombel WJ Sandborn S Schreiber | 2024/1/1 |
Evolution of Symptoms After Ustekinumab Induction Therapy in Patients With Crohn’s Disease | Clinical Gastroenterology and Hepatology | Jean-Frédéric Colombel Bruce E Sands Christopher Gasink Benjamin Yeager Omoniyi J Adedokun | 2024/1/1 |
Achievement of Clinical, Endoscopic, and Histological Outcomes in Patients with Ulcerative Colitis Treated with Etrasimod, and Association with Faecal Calprotectin and C … | Journal of Crohn's and Colitis | Andres J Yarur Michael V Chiorean Julián Panés Vipul Jairath Jinkun Zhang | 2024/1/20 |
Safety of Ustekinumab in Inflammatory Bowel Disease: Pooled Safety Analysis Through 5 Years in Crohn’s Disease and 4 Years in Ulcerative Colitis | Journal of Crohn's and Colitis | Subrata Ghosh Brian G Feagan Elyssa Ott Christopher Gasink Bridget Godwin | 2024/2/4 |
P902 Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for Crohn’s disease: 2 years results of the LIBERTY-CD study | Journal of Crohn's and Colitis | JF Colombel SB Hanauer WJ Sandborn BE Sands S Schreiber | 2024/1/1 |
SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD … | Gastroenterology | Silvio Danese Jean-Frederic Colombel Stephen Hanauer William Sandborn Bruce Sands | 2024/2/1 |
OP03 Efficacy and safety of the oral selective sphingosine-1-phosphate-1 receptor modulator VTX002 in moderately to severely active Ulcerative Colitis: results from a … | Journal of Crohn's and Colitis | BE Sands R Panaccione G D'Haens S Schreiber A DuVall | 2024/1/1 |
EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS–POST HOC ANALYSIS OF LIBERTY-CD AND … | Inflammatory Bowel Diseases | Stefan Schreiber Jean-Frederic Colombel Stephen Hanauer William Sandborn Bruce Sands | 2024/2/1 |
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn’s Disease | Inflammatory Bowel Diseases | Reena Khanna Brian G Feagan Guangyong Zou Larry W Stitt John WD McDonald | 2024/4/25 |
DOP11 Disease clearance after 16 weeks of treatment with vedolizumab in patients with moderate to severe Ulcerative Colitis: An interim analysis from the VERDICT trial | Journal of Crohn's and Colitis | V Jairath G Zou S Adsul JF Colombel GR D’Haens | 2024/1/1 |
Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial | The Lancet Gastroenterology & Hepatology | Silvio Danese Remo Panaccione Brian G Feagan Anita Afzali David T Rubin | 2024/2/1 |
Exposure–efficacy relationship of vedolizumab subcutaneous and intravenous formulations in Crohn’s disease and ulcerative colitis | Geert D’Haens Maria Rosario Daniel Polhamus Nathanael L Dirks Chunlin Chen | 2024/4/2 | |
Clinical Trial Design in Ulcerative Colitis: Interpreting Evolving Endpoints Based on Post Hoc Analyses of the Vedolizumab Phase 3 Trials GEMINI 1 and VISIBLE 1 | Crohn's & Colitis 360 | William J Sandborn Bruce E Sands Sharif Uddin Rana M Qasim Khan Richa Sagar Mukherjee | 2024/1/1 |
Determining the optimal treatment target in patients with ulcerative colitis: rationale, design, protocol and interim analysis for the randomised controlled VERDICT trial | BMJ Open Gastroenterology | Vipul Jairath Guangyong Zou Zhongya Wang Shashi Adsul Jean-Frederic Colombel | 2024/2/1 |
Efficacy of vedolizumab during intravenous induction therapy in ulcerative colitis and Crohn’s disease: post hoc analysis of patient-reported outcomes from the VISIBLE 1 and 2 … | European Journal of Gastroenterology & Hepatology | Geert D’Haens Filip Baert Silvio Danese Taku Kobayashi Edward V Loftus Jr | 2024/4/1 |
Rapid and sustained symptom relief in patients with ulcerative colitis treated with filgotinib: data from the phase 2b/3 SELECTION trial | Official journal of the American College of Gastroenterology| ACG | Silvio Danese Marc Ferrante Brian G Feagan Laurent Peyrin-Biroulet Toshifumi Hibi | 2023/1/1 |
A tissue atlas of ulcerative colitis revealing evidence of sex-dependent differences in disease-driving inflammatory cell types and resistance to TNF inhibitor therapy | Science advances | Aaron T Mayer Derek R Holman Anav Sood Utkarsh Tandon Salil S Bhate | 2023/1/20 |
OP39 Safety of ustekinumab in IBD: Final pooled long-term safety analysis through 5 years in CD and 4 years in UC | Journal of Crohn's and Colitis | S Ghosh B Feagan E Ott C Gasink C Marano | 2023/2/1 |
P696 Design and rationale for the multicentre, randomised, controlled VERDICT trial to determine the optimal treatment target in patients with ulcerative colitis | Journal of Crohn's and Colitis | V Jairath G Zou G Radulescu J Sigler SC Mcfarlane | 2023/2/1 |
A serum biomarker panel can accurately identify mucosal ulcers in patients with Crohn’s disease | Inflammatory bowel diseases | Ariela K Holmer Brigid S Boland Siddharth Singh Jennifer Neill Helen Le | 2023/4/1 |
